AD Scientific Index
 Open Nav
Login Login Pricing & Plans Pricing & Plans
Peter Borchmann

Peter Borchmann

Universität zu Köln - Köln / Germany
Others
AD Scientific Index ID: 5109109
University of Cologne
person_outline Peter Borchmann's MOST POPULAR ARTICLES
1-) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma New England Journal of Medicine 380 (1), 45-56, 2019
2-) Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma New England Journal of Medicine 363 (7), 640-652, 2010
3-) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy Journal of Clinical Oncology 30 (6), 631-636, 2012
4-) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial The Lancet 379 (9828), 1791-1799, 2012
5-) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group … Journal of Clinical Oncology 28 (27), 4199-4206, 2010